146 related articles for article (PubMed ID: 10221167)
21. Human and animal spongiform encephalopathies are the result of chronic autoimmune attack in the CNS: a novel medical theory supported by overwhelming experimental evidence.
Zhu BT
Histol Histopathol; 2005 Apr; 20(2):575-92. PubMed ID: 15736062
[TBL] [Abstract][Full Text] [Related]
22. Prion diseases and the 'protein only' hypothesis: a theoretical dynamic study.
Laurent M
Biochem J; 1996 Aug; 318 ( Pt 1)(Pt 1):35-9. PubMed ID: 8761449
[TBL] [Abstract][Full Text] [Related]
23. Prion-induced neuronal damage--the mechanisms of neuronal destruction in the subacute spongiform encephalopathies.
Giese A; Kretzschmar HA
Curr Top Microbiol Immunol; 2001; 253():203-17. PubMed ID: 11417136
[TBL] [Abstract][Full Text] [Related]
24. Structuring the puzzle of prion propagation.
Eghiaian F
Curr Opin Struct Biol; 2005 Dec; 15(6):724-30. PubMed ID: 16263262
[TBL] [Abstract][Full Text] [Related]
25. The emerging principles of mammalian prion propagation and transmissibility barriers: Insight from studies in vitro.
Surewicz WK; Jones EM; Apetri AC
Acc Chem Res; 2006 Sep; 39(9):654-62. PubMed ID: 16981682
[TBL] [Abstract][Full Text] [Related]
26. Cellular prion protein is expressed on endothelial cells and is released during apoptosis on membrane microparticles found in human plasma.
Simák J; Holada K; D'Agnillo F; Janota J; Vostal JG
Transfusion; 2002 Mar; 42(3):334-42. PubMed ID: 11961239
[TBL] [Abstract][Full Text] [Related]
27. Charged bipolar suramin derivatives induce aggregation of the prion protein at the cell surface and inhibit PrPSc replication.
Nunziante M; Kehler C; Maas E; Kassack MU; Groschup M; Schätzl HM
J Cell Sci; 2005 Nov; 118(Pt 21):4959-73. PubMed ID: 16219680
[TBL] [Abstract][Full Text] [Related]
28. Mapping of possible prion protein self-interaction domains using peptide arrays.
Rigter A; Langeveld JP; Timmers-Parohi D; Jacobs JG; Moonen PL; Bossers A
BMC Biochem; 2007 Apr; 8():6. PubMed ID: 17430579
[TBL] [Abstract][Full Text] [Related]
29. Transmissible spongiform encephalopathies.
Liemann S; Glockshuber R
Biochem Biophys Res Commun; 1998 Sep; 250(2):187-93. PubMed ID: 9753605
[TBL] [Abstract][Full Text] [Related]
30. KDEL-tagged anti-prion intrabodies impair PrP lysosomal degradation and inhibit scrapie infectivity.
Vetrugno V; Cardinale A; Filesi I; Mattei S; Sy MS; Pocchiari M; Biocca S
Biochem Biophys Res Commun; 2005 Dec; 338(4):1791-7. PubMed ID: 16288721
[TBL] [Abstract][Full Text] [Related]
31. Cell culture models of transmissible spongiform encephalopathies.
Béranger F; Mangé A; Solassol J; Lehmann S
Biochem Biophys Res Commun; 2001 Nov; 289(2):311-6. PubMed ID: 11716473
[TBL] [Abstract][Full Text] [Related]
32. [Prion biology: update].
Weber EL
Rev Argent Microbiol; 1999; 31(4):205-18. PubMed ID: 10615684
[TBL] [Abstract][Full Text] [Related]
33. The Ninth Datta Lecture. Molecular biology of transmissible spongiform encephalopathies.
Weissmann C
FEBS Lett; 1996 Jun; 389(1):3-11. PubMed ID: 8682199
[TBL] [Abstract][Full Text] [Related]
34. Glycosylation of prion strains in transmissible spongiform encephalopathies.
Atkinson PH
Aust Vet J; 2004 May; 82(5):292-9. PubMed ID: 15181931
[TBL] [Abstract][Full Text] [Related]
35. Separation of native prion protein (PrP) glycoforms by copper-binding using immobilized metal affinity chromatography (IMAC).
Müller H; Strom A; Hunsmann G; Stuke AW
Biochem J; 2005 May; 388(Pt 1):371-8. PubMed ID: 15658935
[TBL] [Abstract][Full Text] [Related]
36. Does transmissibility necessarily imply infectivity in spongiform encephalopathy?
Agius LM
Med Hypotheses; 2003 Jun; 60(6):886-92. PubMed ID: 12699719
[TBL] [Abstract][Full Text] [Related]
37. Expression and characterisation of fully posttranslationally modified cellular prion protein in Pichia pastoris.
Marbach J; Zentis P; Ellinger P; Müller H; Birkmann E
Biol Chem; 2013 Nov; 394(11):1475-83. PubMed ID: 23893688
[TBL] [Abstract][Full Text] [Related]
38. Analysis of prion strains by PrPSc profiling in sporadic Creutzfeldt-Jakob disease.
Schoch G; Seeger H; Bogousslavsky J; Tolnay M; Janzer RC; Aguzzi A; Glatzel M
PLoS Med; 2006 Feb; 3(2):e14. PubMed ID: 16354106
[TBL] [Abstract][Full Text] [Related]
39. [Molecular bases of prion diseases].
Rać M; Rać M
Ann Acad Med Stetin; 2006; 52(3):5-13. PubMed ID: 17385343
[TBL] [Abstract][Full Text] [Related]
40. Species barrier in prion diseases: a kinetic interpretation based on the conformational adaptation of the prion protein.
Kellershohn N; Laurent M
Biochem J; 1998 Sep; 334 ( Pt 3)(Pt 3):539-45. PubMed ID: 9729459
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
